Inventor · disambiguated record
Maija-Leena Hollmén
Also filed as: HOLLMEN MAIJA · HOLLMÉN MAIJA-LEENA
2 granted patents·8 pending applications·0 citations·filing 2009–2023
26Inventor score
Top patents by PatentIndex Score
10 records- 0149US2025327806A1Method for identifying cancer patients that benefit from anti-clever-1 treatmentFARON PHARMACEUTICALS OY·Filed 2023·Application pending·0 cites
- 0249US2025383356A1Method for identifying cancer patients that benefit from anti-clever-1 treatmentFARON PHARMACEUTICALS OY·Filed 2023·Application pending·0 cites
- 0346US2011293614A1Isoform specific anti-her4 antibodiesELENIUS KLAUS·Filed 2009·Application pending·0 cites
- 0445US2022227858A1Controlling of immune activation by soluble clever-1FARON PHARMACEUTICALS OY·Filed 2022·Application pending·0 cites
- 0542US9963517B2Isoform specific anti-HER4 antibodiesGENENTECH INC·Filed 2015·Granted May 8, 2018·0 cites·3 claims
- 0638US2022404366A1Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatmentFARON PHARMACEUTICALS OY·Filed 2020·Application pending·0 cites
- 0736US10884000B2Method of monitoring the efficacy of the anti-clever-1 therapy in cancerFARON PHARMACEUTICALS OY·Filed 2017·Granted Jan 5, 2021·0 cites·4 claims
- 0835US2021087264A1Anti-clever-1 agents for controlling lysosomal vatpase proton pumps to increase lysosomal ph-value and the cross-presentation of digested matterFARON PHARMACEUTICALS OY·Filed 2020·Application pending·0 cites
- 0934US2021371865A1Tlr9 agonists for use in downregulating clever-i expression on alternatively activated macrophagesFARON PHARMACEUTICALS OY·Filed 2019·Application pending·0 cites
- 1030US2021261657A1Treatment of cancer with clever-1 inhibition in combination with pd-1/pd-l1 inhibitorFARON PHARMACEUTICALS OY·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Maija-Leena Hollmén files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →